Irven (Irbesartan)

Irbesartan selectively antagonizes the AT1 receptor for angiotensin II, blocking the hormone’s vasoconstrictive and aldosterone‑secreting actions. This results in relaxed blood vessels, reduced peripheral resistance, and decreased sodium‑water retention, which together lower blood pressure and protect the heart and kidneys.

The appropriate dose of Irven is determined by the prescribing clinician based on the individual’s blood pressure, renal function, and overall clinical condition. Dosage adjustments may be required for patients with impaired kidney function or those taking interacting medications.

Irbesartan is classified as contraindicated in the second and third trimesters of pregnancy because it can cause fetal toxicity. Safety during breastfeeding has not been established, so the drug should be used only if the potential benefit justifies the potential risk to the infant.

To order Irven, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irven (irbesartan) shares the same mechanism as other ARBs, offering effective blood‑pressure control with a lower incidence of cough compared with ACE inhibitors. Compared with some ARBs, irbesartan has a longer half‑life, allowing once‑daily dosing, and it is well‑studied for renal protection in diabetic patients.

Irven should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and heat sources. Do not store in the bathroom or near a kitchen sink to maintain product stability.

Irven is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a full glass of water and not crushed or chewed unless specifically advised by a healthcare professional.

Serious risks include angioedema, severe hyperkalemia, acute kidney injury, and hepatic dysfunction. Patients should be monitored for swelling of the face or throat, sudden changes in kidney function, or unexplained fatigue, and they should seek immediate medical attention if such symptoms occur.

Irven should be avoided in patients with known hypersensitivity to irbesartan or any component of the formulation, in those taking concomitant ACE inhibitors or other ARBs, and in pregnant women during the second and third trimesters. Caution is also advised for individuals with severe renal impairment.